Pampers parents probably did not spend much time thinking about Procter & Gamble’s push into premium wellness or AI driven supply chains, but shareholders could not ignore what happened to the equity. Holding Procter & Gamble from the start of the year would have returned 20.0%, including dividends. If you were deciding on 1 January 2026 whether to buy, what would you have needed to believe about those planned product launches, restructuring and buybacks before any of this news arrived?
On Simply Wall St, a Narrative is an investor's thesis written down: the reasoning, plus the numbers it rests on. Run those numbers and you get an estimated Fair Value.
The easy part of this move is behind Procter & Gamble. Zero in on 38 high quality undervalued stocks for companies trading below our estimates.
The Argument You Would Have Had To Settle On Procter & Gamble
The shares cost US$143 at the start of the period, so any decision on Procter & Gamble came down to which story you trusted more.
The bullish narrative put fair value at US$171. It rested on product investment lifting market share, with analysts assuming revenue growth of 3.3% a year and profit margins rising from 18.6% to 19.2%, supported by share buybacks.
The bearish view set fair value at US$120. That thesis expected revenue growth of 4.7% with profit margins at 17.0%, and treated a future P/E of 23.0x over a 5 year window as sufficient given slowing momentum.
What The Procter & Gamble Results Put To The Test
The planned Thorne acquisition in premium wellness backed the bullish view that Procter & Gamble could lean on higher value health products. Q1 2027 figures gave a mixed read though. Revenue moved to US$23,276m from US$22,386m while net income slipped to US$4,659m from US$4,677m and net margin eased to 20.0% from 20.9%. Overall, the evidence cut both ways.
The hinge assumption was margin expansion. For another stock, you would check whether net margin and absolute profit move in the direction the upbeat story assumes once new product bets start to show up in reported results.
What Today's Procter & Gamble Price Already Assumes
Today Procter & Gamble trades at US$165 from the start of the year, with this cautious Narrative’s Fair Value sitting below that level rather than above it.
The Narrative leans on solid returns on capital and a wide moat, yet worries about pricing power as competition pressures margins. A buyer here is effectively assuming those profitability metrics hold up. How does that square with the source’s concern about margin compression as rivals push harder on price?
"Procter & Gamble operates within a very competitive environment. However, its higher operating margins and wide moat are a clear sign it still operates with competitive advantages over its competitors, as well as having the capability of raising prices if needed."
One Narrative disagrees with today's price. → See where this Narrative says Procter & Gamble should trade
Which Company Could Surprise You Next?
You may be late to this rally, but that does not have to mean arriving late to every opportunity. Start with companies whose prices leave room for a different view of their future. Here are three trading below our estimates.
- Company 1 - 19% below our estimate - focuses on custom security hardware and a single operating system for long-term integration.
- Company 2 - 40% below our estimate - supplies full-stack accelerated computing platforms as customers expand large AI infrastructure commitments.
- Company 3 - 49% below our estimate - scales an asset-light hotel network while attaching a retail platform to each guest stay.
That is three of the list. See every one of the 25 solid balance sheet companies →
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com